Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications

Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications

<p style="text-align:justify;"> Endogenous damage-associated molecular patterns (DAMPs) are released during tissue damage and have increasingly recognized roles in the etiology of many human diseases. The inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn’s disease...

Descripció completa

Dades bibliogràfiques
Autors principals:	Boyapati, R, Rossi, A, Satsangi, J, Ho, G
Format:	Journal article
Publicat:	Springer Nature 2016

Ítems similars

Biomarkers in search of precision medicine in IBD
per: Boyapati, R, et al.
Publicat: (2016)

Mitochondrial DNA is a pro-inflammatory damage-associated molecular pattern released during active IBD
per: Boyapati, R, et al.
Publicat: (2018)

Regulation of Mucosal Immune Responses – The Missing Link in IBD?
per: Charles O Elson, et al.
Publicat: (1996-01-01)

MicroRNAs: new players in IBD
per: Kalla, R, et al.
Publicat: (2014)

TNF Promoter Hypomethylation Is Associated With Mucosal Inflammation in IBD and Anti-TNF Response
per: Daniel S. Levic, et al.
Publicat: (2024-01-01)

Editorial: the influence of genetic factors in mediating the effects of tobacco smoke in IBD
per: Adams, A, et al.
Publicat: (2017)

The Gut-Brain Axis in IBD: An Investigator’s Perspective
per: Stephen M Collins, et al.
Publicat: (1995-01-01)

Top-down in the long term in Crohn's disease
per: Boyapati, R, et al.
Publicat: (2018)

Editorial: what can be done when infliximab stops working in ulcerative colitis?
per: Boyapati, R, et al.
Publicat: (2015)

Targeting microbial pathogenic mechanisms as a novel therapeutic strategy in IBD
per: Paul F. Miller
Publicat: (2024-08-01)

Can thiopurines prevent formation of antibodies against tumor necrosis factor antagonists after failure of these therapies?
per: Boyapati, RK, et al.
Publicat: (2016)

Gut microbiota and blood biomarkers in IBD-Related arthritis: insights from mendelian randomization
per: Wei Yang, et al.
Publicat: (2025-01-01)

Extracellular Vesicles with Possible Roles in Gut Intestinal Tract Homeostasis and IBD
per: Xin Chang, et al.
Publicat: (2020-01-01)

Neutrophils: Old cells in IBD, new actors in interactions with the gut microbiota
per: Camille Danne
Publicat: (2024-06-01)

The Role of Vitamin D in the Pathomechanism of Inflammatory Bowel Disease (IBD) and its Therapeutic Implications - a literature review
per: Wiktoria Maria Tomaszewska, et al.
Publicat: (2025-01-01)

The IBD2 locus shows linkage heterogeneity between ulcerative colitis and Crohn disease.
per: Parkes, M, et al.
Publicat: (2000)

SARS-CoV-2 vaccination in IBD: past lessons, current evidence and future challenges
per: Wellens, J, et al.
Publicat: (2021)

How to apply for and secure EU funding for collaborative IBD research projects
per: Satsangi, J, et al.
Publicat: (2016)

Gut microbiota in MAFLD: therapeutic and diagnostic implications
per: Waleed Alghamdi, et al.
Publicat: (2024-04-01)

Mediators of Gut Mucosal Immunity and Inflammation
per: Ishak Ozel Tekin, et al.
Publicat: (2015-01-01)

Lean MASLD and IBD: Exploring the Intersection of Metabolic Dysfunction and the Gut–Liver Axis
per: Adrian Rotaru, et al.
Publicat: (2025-02-01)

Novel approaches in IBD therapy: targeting the gut microbiota-bile acid axis
per: Yinping Pan, et al.
Publicat: (2024-12-01)

Leaky gut, circulating immune complexes, arthralgia, and arthritis in IBD: coincidence or inevitability?
per: Xi-ya Jin, et al.
Publicat: (2024-03-01)

Anti-SARS-CoV-2 antibody responses in patients with IBD treated with biologics - are we finding CLARITY?
per: Chapman, TP, et al.
Publicat: (2021)

Therapeutic Potential of Tolerogenic Dendritic Cells in IBD: From Animal Models to Clinical Application
per: Raquel Cabezón, et al.
Publicat: (2013-01-01)

IBD and Diet
per: Ilene Gilbert, et al.
Publicat: (1994-01-01)

IBD and IBS : novel mechanisms and future practice /
per: Falk Symposium (170th : 2009 : Glasgow, Scotland), et al.
Publicat: (c201)

The contribution of OCTN1/2 variants within the IBD5 locus to disease susceptibility and severity in Crohn’s disease
per: Noble, C, et al.
Publicat: (2005)

Advancing Therapeutic Targets in IBD: Emerging Goals and Precision Medicine Approaches
per: Lucia Centanni, et al.
Publicat: (2025-01-01)

Lactococcus lactis, A Tool for the Delivery of Therapeutic Proteins Treatment of IBD
per: Lothar Steidler
Publicat: (2001-01-01)

Year in microbiota: IBD clinical studies
per: T. Jayawardana, et al.
Publicat: (2023-10-01)

Neuromodulation and the Gut–Brain Axis: Therapeutic Mechanisms and Implications for Gastrointestinal and Neurological Disorders
per: Baha’ Aljeradat, et al.
Publicat: (2024-05-01)

Diverse but desolate landscape of gut microbial azoreductases: A rationale for idiopathic IBD drug response
per: Joshua B. Simpson, et al.
Publicat: (2023-12-01)

The Impact of PPARγ Genetic Variants on IBD Susceptibility and IBD Disease Course
per: Jessica Mwinyi, et al.
Publicat: (2012-01-01)

IBD: Progress in Pathogenesis
per: Claudio Fiocchi, et al.
Publicat: (1993-01-01)

Etiology of Organ-Specific Autoimmunity: Basic Research and Clinical Implications in IBD
per: George S Eisenbarth
Publicat: (1996-01-01)

Host-gut microbiota derived secondary metabolite mediated regulation of Wnt/β-catenin pathway: a potential therapeutic axis in IBD and CRC
per: Sushma S. Kumar, et al.
Publicat: (2024-04-01)

Biosimilars in IBD: hope or expectation?
per: Gecse, K, et al.
Publicat: (2013)

The Role of IL-33 in Gut Mucosal Inflammation
per: Luca Pastorelli, et al.
Publicat: (2013-01-01)

Mucosal Immunity and Trained Innate Immunity of the Gut
per: Tsvetelina Velikova, et al.
Publicat: (2024-08-01)